anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aim of the proposed supplemental study is to test a single session motivational interviewing (MI) program designed to promote the acceptance and use of PrEP for high-risk young Black men who have sex with men (YBMSM) and to determine whether previous assignment to study condition moderates these outcomes. In the parent study we had the foresight to include a cross-sectional survey of men's attitudes toward PrEP use as part of their first follow-up assessment. Using that data, we will identify the predictors of readiness to accept PrEP and we will use these findings to inform the design of a brief Motivational Interviewing session (MI-PrEP) that will promote uptake of PrEP. We will enroll 65 YBMSM who have completed the 12-month follow-up assessment from the parent study and 35 YBMSM (same inclusion criteria) from either of two clinics used in the parent study (the Crossroads Clinic or the Open Arms Clinic) who did not participate in the parent study. Using small block randomization, these 100 men will be assigned to the MI-PrEP condition or to the standard of care only control condition. At the conclusion of the enrollment session men will be asked if they would like to schedule an appointment to begin taking PrEP. This same offer will be made again approximately 14 days after the enrollment session. The dependent variables will thus include measures of whether men made/kept an appointment to begin PrEP and, if so, how much time elapsed before doing so and whether they filled the prescription for PrEP. For those who do fill the prescription we will test their blood for levels of tenofovir and emtricitabine after 3 months of time has elapsed. Group differences (Intervention vs. Control) in uptake, time to uptake, and actual use/adherence of PrEP are hypothesized to favor those receiving the MI-PrEP intervention program. If this is the case then an initial body of evidence will exist supporting the potential efficacy of a Motivational Interviewing-based, single session intervention that can be delivered to YBMSM in clinical settings.
PURPOSE:To enhance the keeping stability and stability of the title composition by incorporating metal oxide particles and/or metal hydroxide particles having a specified mean particle diameter and uniformly coated with a silicone compd. to form the water-in-oil type emulsion composition. CONSTITUTION:A silicone compd. expressed by formula I [R1 is a lower alkyl, R2 is a hydrogen atom, an alkyl, and an aryl, (a) is a positive integer, and (b) stands for 0 or a positive integer] is uniformly coated on metal oxide particles and/or metal hydroxide particles having 0.01-1mum mean particle diameter, and the material is incorporated to prepare the water-in-oil type emulsion composition. The (a) and (b) of the silicone compd. expressed by formula I are appropriately limited to conform to 20<=100a/(a+b)<=100. The molecular wt. of the silicone compd. is preferably >=200,000.
Inflammation and oxidative stress (OS) are the major pathogenic characteristics of acute kidney injury (AKI). Studies have shown that Schisandrin (Sch) could regulate inflammatory disease. However, the function and mechanism of Sch in AKI progression are still unknown. Here, we investigated Sch's potential effects and mechanism on mice's renal damage and macrophages induced by lipopolysaccharide (LPS). Sch decreased LPS-induced inflammatory factor production while increasing the activity of related antioxidant enzymes in macrophages and mouse kidney tissues. Hematoxylin and eosin staining revealed that Sch may have the ability to profoundly inhibit inflammatory cell invasion and tissue damage caused by LPS in renal tissue. Furthermore, Western blot and immunohistochemical studies showed that Sch exerted its effects mainly through up-regulation of nuclear factor erythroid 2-related factor 2/heme oxygenase-1 and inhibition of Toll-like receptor 4‒mitogen-activated protein kinases/nuclear factor-kappa B pathways. Collectively, this study illustrates that Sch suppresses LPS-stimulated AKI by descending inflammation and OS, illuminating prospective AKI treatment options.
Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti- cancer treatment. The invention includes the use of cell cycle G2-checkpoint- abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents. Disclosed are compounds of Formulas (II) and (VI):
Subjects will be residents of California or Arizona and recruited to the study via response to the study recruitment questionnaire advertised through online flyers, social media platforms (i.e., facebook and instagram), list serves, and recruitment services across all Arizona State University (ASU) campuses. This 6-week randomized controlled experimental study consists of a 4-week intervention period that immediately follows a 2-week baseline symptom monitoring period. The trial is conducted completely online. Data analyses will begin immediately once the trial is initiated and is expected to occur for up to one year after study completion. Following a 2-week monitoring period, participants will be randomized (via a number draw randomization method) into one of three groups: Machine Learning (ML) App + Registered Dietitian (RD) facilitator (ML-RD), ML mobile application (ML-App), or Standard Dietary Education (CON). The ML-RD group will be provided access to the Heali mobile application as well as a personal RD to provide nutrition support and answer any questions through a real-time messaging system within the mobile app. The ML-APP group receives access to the Heali mobile dietary application only. All groups will receive a link to resources regarding the LFD including an educational guide to the implementation of the elimination and reintroduction phases of the diet, a suitable/unsuitable food guide, 19 substitutes for unsuitable foods, a guide of example meals (i.e., breakfast-6 recipes, lunch-8 recipes, dinner-12 recipes, and snacks/beverages-13 recipes), and tips for reading labels and eating a balanced diet while following the LFD. The website is located at http://www.myginutrition.com/news.html and operated by the University of Michigan Health System.
CLL or SLL with prior exposure to both a Bruton's tyrosine kinase inhibitor (BTKi) and BCL-2 inhibitor, unless previously deemed ineligible for those therapies. Patients enrolled in CLL/SLL arm will be randomized to one of two dose levels. This is the only randomization component in the trial.
Patients aged 18-80 years who confirmed with COVID-19 and classified as severe were enrolled in the study, and then separated randomly into two groups: a berberine group (B group) and a control group (C group). The diagnostic criteria for severe cases are in accordance with the Diagnosis and Treatment Guideline of patients with COVID-19 issued by the National Health Commission of the People's Republic of China (Edition 7). In general, patients diagnosed with COVID-19 pneumonia must also meet any of the following criteria: appears shortness of breath, respiratory rate (RR) ≥ 30 times/min; SPO2 ≤ 93% at rest; the ratio of partial oxygen pressure of arterial blood (PaO2) to oxygen absorption concentration (FiO2) ≤ 300mmHg (1mmHg=0.133KPa); pulmonary imaging showed the lesion progression \>50% within 24-48 hours. All enrolled patients were given general support therapy, oxygen therapy, antiviral drugs, in combination with antibiotics and small doses of glucocorticoids if necessary, nutritional and organ function support. Patients in the berberine group (B group) were given berberine 0.3g tid orally or tube feed daily, while patients in the control group (C group) were given montmorilonite orally if they presence of diarrhea. The duration of the study intervention was 14 days and followed up to discharge. Investigators record general information about patients at admission, including age, gender, age, exposure history, time from onset of symptoms to hospital, APACHE II score, the presentation of X-ray, comorbidity, mechanical ventilation, fever or not,gastrointestinal symptoms. Investigators also evaluate the gastrointestinal function daily,including gastrointestinal symptoms (nausea, vomiting, abdominal pain, abdominal distension or diarrhoea), frequency of diarrhea, the characteristics of stool (Bristol scal). Peripheral blood are collected on day 1,3, 7 and 14 after admission to determine the level of interleukin-6 (IL-6), interleukin-1β (IL-1β), interleukin-10 (IL-10) and tumor necrosis factor (TNF-α). Laboratory tests are also performed to evaluate leucocyte, c-reactive protein (CRP), and procalcitonin (PCT) levels at the same time. Glutamate transaminase (ALT), glutamate transaminase (AST), urea nitrogen (Bun), creatinine, prothrombin time (PT), partially activated prothrombin time (APTT), and Sequential Organ Failure Assessment (SOFA) score are used to evaluate organ function on day 1,3, 7 and 14 after admission. Investigators also record the adverse events associated with the drug, length of stay and the prognosis at discharge. The patients are blinded to the group allocation. Two physicians are responsible for data processing, one is responsible for recording and collecting, and the other is responsible for checking, and they are all blind to the research.
PURPOSE:To prevent the decomposition, etc. of a drug, e.g. an insecticide, by the heat in molding and make the drug advantageously the prolonged release type, by curing a resin with electromagnetic waves, and controlling the release of the drug held by or coated with the resin. CONSTITUTION:The release of a drug selected from an insecticide, rodenticide, repellent, mothproofing agent, germicide, perfume, deodorant, medicine and synergist is controlled by irradiating a photosensitive resin selected from preferably polyester, acrylic, nylon, styrene, polyvinyl alcohol, epoxy, polyurethane and  vinyl acetate, with electromagnetic waves, e.g. ultraviolet or electron rays (X- rays), to cure the resin, and making the drug held by or contained in the resin  the prolonged release type. According to the method, the volatilization, blooming phenomenon and operability of the drug in molding is improved to give the excellent prolonged release effect of the drug.
A system for controlling the distribution of pharmaceuticals involves tracking the distribution of pharmaceutical products and managing pharmaceutical rebates via the internet. The system provides for the verification, payment and auditing of the rebates. Before the pharmacy can participate in the rebate scheme they must first undergo an initial registration process  110.  Following registration, the pharmacy may purchase pharmaceutical products which are supplied from the manufacturer via a supply chain  120.  The pharmaceuticals are supplied at a standard supply price, irrespective of the country in which the retailers are located. When the pharmaceuticals are supplied to an end user, e.g. a patient, the pharmacy enters a rebate claim  130,  which is processed by an international clearing centre  140.  Provided the processing has a successful outcome, the pharmacy receives a rebate payment  150,  the size of which depends upon the country in which the pharmacist is located. This allows the dispensing of prescription pharmaceuticals at a discount to the patient and reduces the prevalence of parallel importation.
OBJECTIVES: Aortic pathologies often present with elevated inflammatory biomarkers due to the nature of the disease. Open aortic surgery causes significant trauma to the body due to often mandatory ischemic periods, long cardiopulmonary bypass times and polytransfusion. We aim to determine postoperative trends on inflammation biomarkers for different aortic pathologies and type of surgery in different segments of the aorta.
METHODS: Retrospective review of prospectively collected data of 193 consecutive patients who underwent aortic surgery in our centre between 2017 and 2021, grouped according to the type of aortic intervention: (1) Type A aortic dissection (AD) repair with ascending aorta/hemiarch replacement, (2) Aortic root replacement (ARR), (3) Aortic arch + Frozen elephant trunk (FET), (4) Descending thoracic aorta (DTA)/Thoraco-Abdominal aortic repair (TAA). Primary outcomes were daily values of white blood cells (WBC) and C-Reactive Protein (CRP) during the first 15 postoperative days.
RESULTS: All groups had a similar inflammatory peak in the first 2-4 days (WBC 12-15 × 109 c/L). AD and FET groups show similar trends with WBC and CRP peaks on days 2 and 10. The ARR group didn't experience the 2nd peak as most patients were already discharged. DTA/TAA patients experienced a more prolonged inflammatory response, reaching a plateau by day 5-10. AD group shows the highest WBC levels and the DTA/TAAA group the highest CRP levels. CRP levels remain elevated (100-200 mg/L) in all groups after 15 postoperative days.
CONCLUSIONS: Inflammatory biomarkers show different postoperative trends depending on the clinical presentation and complexity of the aortic procedure performed. Further understanding of the inflammatory response to different aortic pathologies and surgical procedures will permit reduction on the liberal use of antibiotics that this cohort of patients are usually exposed to. An earlier version of the data included in this manuscript was presented as Oral Abstract in the UK Society of Cardiothoracic Surgery Annual meeting in 2021.
Patients with chronic kidney disease (CKD) are exquisitely salt-sensitive. Salt-sensitivity in CKD is linked to hypertension and cardiovascular outcomes. Dietary salt restriction is an accepted intervention for salt-sensitivity in CKD. Another strategy, however, could be to block sodium uptake by the kidney pharmacologically by diuretics. Especially diuretics acting on the distal tubule may be effective, because this appears to be the site of increased sodium reabsorption in CKD. It is currently unknown how these two strategies, diet or diuretics, relate. The investigators hypothesize that diuretics are non-inferior to diet.
PURPOSE: An eye drop composition for preventing and treating ophthalmologic diseases containing hyaluronic acid and carboxymethylcellulose is provided to improve osmosis and penetration. CONSTITUTION: An eye drop composition for preventing and treating ophthalmologic diseases contains hyaluronic acid or its pharmaceutically acceptable salt, carboxymethylcellulose or its pharmaceuitcallly acceptable salt, isotonic agent, buffer, stabilizer, preserver, pH adjusting agent, or solvent. The pharmaceutically acceptable salt is sodium, potassium, or calcium. The isotonic agent is sodium chloride or potassium chloride. The buffer is aminocaproic acid, sodium dihydrogenphosphate. The stabilizer is disodium edentate or sodium perborate. The preserving agent is benzalkonium chloride, methylparaben or ethylparaben. The eye drop is liquid type.
FIELD: pharmaceutics. SUBSTANCE: invention provides novel composition containing (i) at least one greasy, oily, and sticky substance and at least one pharmaceutically active substance or (ii) at least one pharmaceutically active substance, which itself is greasy, oily, and sticky. Composition is in the form of a multitude porous inorganic particles consisting of ceramic hydroxyapatite 20 to 150 mcm in diameter and with nominal diameter of pores 5 to 100 mcm and porosity 50 to 70 vol %, which particles include indicated substances. Content of component (i) or (ii) constitutes 15-40%, whereas molecular weight of pharmaceutically active substance is less than 1000 Da. Composition is prepared by mixing 15-40% of component (i) or (ii) and indicated amount of porous inorganic particles. Composition is dry and easy to handle. EFFECT: increased drug liberation rate. 7 cl, 5 ex
Conjugation of polymers to proteins, including biomedically-relevant PEGylation, is a promising approach to address a central challenge of biologics and biotech: the lack of protein stability in demanding non-native environments. Application of conjugation is hindered by the lack of atomic level understanding of protein-polymerinteractions, preventing design of conjugates with predicted properties. An integrative structural and biophysical approach was used to address this challenge using a polymer-modified carbohydrate recognition domain of human galectin-3 (Gal3C), a lectin essential for cellular adhesion and potential biologic. Modification with PEG and other polymers dramatically increased Gal3C thermal stability and redirected its unfolding pathway through forming a stable intermediate. Distinct polymer properties which increased protein thermal stability were revealed. Structural details of Gal3C-polymer conjugates revealed by NMR pointed to the important role of polymer localization. Residues local to the site of conjugation were perturbed by polymer conjugation and these perturbations remained localized over a wide temperature range. For PEGylated conjugates, replacing key lysine residues within the PEG-perturbed region altered the protein-PEG interface and thermal unfolding behavior, providing mechanistic insight into rational design of conjugates that will expand the benefits of polymer conjugation.
A 65-year-old male complained of persistent melena for 6 days, and displayed anemia symptoms without hematemesis, vomiting, and abdominal distention. He was diagnosed as ruptured aneurysm of aortic sinus Valsalva, and had received coronary artery occlusion 1 month ago. After the operation, he was continually prescribed clopidogrel 75 mg once daily. The laboratory examination showed blood hemoglobin concentration was 60 g/L without other conspicuous abnormality. Unfortunately, neither esophagogastroduodenoscopy (EGD) nor colonoscopy found no obvious bleeding lesions. And abdominal computed tomography angiography (CTA) and enhanced computed tomography (CT) showed no obvious abnormal findings. Moreover, capsule endoscopy revealed small intestinal with mucosal erosion (Figure 1A). After discontinued clopidogrel, blood transfusion, and support therapy, his symptoms was resolved with negative fecal occult blood, continued clopidogrel 75 mg once daily, and uneventfully discharged 1 week later.
FIELD: pharmaceutic-chemical industry. SUBSTANCE: marigold top raw material is extracted in a 24-26 % alcoholic solution, raw-extractant ratio of 1: (10-12), at 50-60 C for 1.5-2 hrs. The resulting supernatant is decanted, and the residue is extracted and decanted again. The combined extractive layers are filtered, the filtrate is evaporated and dried to give the end product. The evaporation of filtrate is carried outto solid residue content of 115-20 % . The end product is dried at air temperature 160-140 C at inlet and 80-75 C at outlet and air mixture flow rate being 2-2.5 l/h. EFFECT: increased efficiency. 2 cl
Provided is a  Bifidobacterium lactis.  The  Bifidobacterium lactis  is  Bifidobacterium animalis subsp. lactis  BL-11, and the preservation number of the  Bifidobacterium animalis subsp. lactis  BL-11 is CGMCC No. 20847. The provided  Bifidobacterium animalis subsp. Lactis  can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit/hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.
Chronic hepatitis C Virus (HCV) infection presents a global health challenge, with significant morbidity and mortality worldwide. Despite remarkable progress in treatment options, achieving elimination targets by 2030, as set by the World Health Organization, remains elusive. Our study aimed to address this gap by integrating HCV screening into a national breast cancer screening program. Between March 2022 and March 2023, a prospective cross-sectional multicenter study was conducted in four radiology centers in Montpellier, France. We proposed HCV screening to consecutive women undergoing mammography, targeting 1,500 participants aged 50-74 years. A rapid diagnostic test (RDT) for HCV antibodies (HCV Ab) was performed on capillary whole blood, with positive cases undergoing serological and RNA confirmation. Participants also completed a questionnaire on demographic data and risk factors. Acceptance rates, HCV prevalence, and linkage to care were assessed. The acceptance rate for this integrated screening approach was 82.4%. Notably, the seroprevalence of HCV was found to be 0.65%. Linkage to care was prompt, and the cascade of care demonstrated successful treatment outcomes. Importantly, the majority of detected infections were successfully resolved. These findings underscore the feasibility and acceptability of integrating HCV screening with breast cancer screening programs providing updated prevalence data and valuable insights for refining future screening strategies.
FIELD: microbiology.SUBSTANCE: invention relates to microbiology and relates to a method for the eradication ofHelicobacter pyloribacteria in experimental helicobacteriosis in conventional white mice. The essence of the method lies in the fact that intramuscular administration of a synthetic glucocorticoid preparation Dexamethasone at a dose of 40 mcg per day is carried out intramuscularly for five days to each conventional white mouse, followed after 24 hours by oral administration to white mice for four days of a suspension ofH. pyloriKM-11RifRbacteria on isotonic sodium chloride solution once a day. The introduction of a suspension of bacteriaH. pyloriKM-11 RifRis continued, daily sampling feces to determine the amount ofH. pyloriexcreted from the body of white mice, by sowing feces on a selective hemin-containing dense nutrient medium with rifampicin. 24 hours after the end of the oral administration ofH. pyloriKM-11RifRon the sixth day, all conventional white mice are injected with a drug consisting of 0.2 ml of a suspension of distilled water mixture of metaprebiotic Stimbifid plus and nanostructured preparation Sky-force. The absence of viable bacteria in Petri dishes confirms the complete eradication of the pathogen from the animal body.EFFECT: use of the method allows for the eradication ofH. pyloriin experimental helicobacteriosis in laboratory animals.3 cl, 1 dwg, 4 ex
PURPOSE: A makeup cosmetic composition having a separate transparent phase is provided to enhance preference and adhesion to skin. CONSTITUTION: A cosmetic composition comprises a transparent layer of oil phase or aqueous phase. The refractive index of the transparent layer is 1.48. The transparent layer contains 5.00-7.99 wt% of useful tackifier. The useful tackifier is dextrin myristate or dextrin palmitate. The transparent layer contains organic UV protection agent. The transparent layer contains 0.20-0.40 wt% of aqueous tackifier and carbomer. The composition is a cosmetic composition for makeup.